Juno Therapeutics (JUNO) Misses Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. MSFT
3. SPY
4. CSCO
5. KTOS

6. PLTR
7. MRK
8. TRAX
9. NVDA
10. JPM

Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results

March 1, 2017 4:05 PM EST

Nine product candidates in clinical trials against eight different targets

Pivotal trial for JCAR017 in r/r DLBCL expected to start in 2017

Phase I JCAR017 demonstrates 80% overall response and 60% complete response in r/r DLBCL

Discontinuing development of JCAR015 in r/r adult ALL to focus on defined cell product in this setting

2016 year end cash position of $922.3 million

2017 cash burn guidance of $270 million to $300 million, including $22 million to $27 million in capital expenditures

Conference call today at 5:00 p.m. Eastern Time

... More